- Home
- RNA
as 03-28-2025 4:00pm EST
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.7B | IPO Year: | 2020 |
| Target Price: | $68.25 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.56 - $56.00 | Next Earning Date: | 05-08-2025 |
| Revenue: | $10,897,000 | Revenue Growth: | 13.98% |
| Revenue Growth (this year): | -39.48% | Revenue Growth (next year): | 230.08% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boyce Sarah | RNA | President and CEO | Mar 20 '25 | Sell | $31.06 | 31,540 | $979,563.01 | 305,871 | |
| MacLean Michael F | RNA | Chief Financial Officer | Mar 20 '25 | Sell | $31.06 | 7,935 | $246,424.60 | 96,720 | |
| Flanagan W. Michael | RNA | Chief Scientific Officer | Mar 20 '25 | Sell | $31.06 | 11,780 | $365,867.95 | 80,195 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Mar 20 '25 | Sell | $31.06 | 7,778 | $241,583.12 | 97,130 | |
| Hughes Steven George | RNA | Chief Medical Officer | Mar 20 '25 | Sell | $31.06 | 9,578 | $297,490.76 | 72,850 | |
| Flanagan W. Michael | RNA | Chief Scientific Officer | Mar 11 '25 | Sell | $30.13 | 20,000 | $602,614.00 | 80,195 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | Mar 3 '25 | Sell | $29.41 | 5,875 | $172,807.25 | 50,554 | |
| Gallagher Kathleen P. | RNA | Chief Program Officer | Feb 3 '25 | Sell | $32.16 | 5,875 | $188,918.26 | 50,554 | |
| Boyce Sarah | RNA | President and CEO | Jan 21 '25 | Sell | $28.59 | 10,397 | $297,291.42 | 305,871 | |
| LEVIN ARTHUR A | RNA | Director | Jan 21 '25 | Sell | $28.60 | 1,872 | $53,536.77 | 12,958 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
PR Newswire
8 days ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
12 days ago
Sector Update: Health Care Stocks Decline Premarket Monday
MT Newswires
12 days ago
Sector Update: Health Care
MT Newswires
12 days ago
Avidity Biosciences Reports Positive Topline Data From Phase 1/2 Trial of Del-Zota to Treat DMD
PR Newswire
12 days ago
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
MT Newswires
16 days ago
Citigroup Initiates Avidity Biosciences Inc at Buy With $70 Price Target
MT Newswires
17 days ago
Avidity Biosciences Insider Sold Shares Worth $602,614, According to a Recent SEC Filing
PR Newswire
17 days ago
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.